Form 4: ANI Pharma CFO Acquires Shares, Reports Tax Withholding

ANI Pharmaceuticals' SVP & CFO, Stephen P. Carey, reported the acquisition of 22,233 restricted shares and the disposition of 2,773 shares for tax purposes.

Summary

• Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals Inc. (ANIP), acquired 22,233 shares of common stock.
• The acquisition occurred on February 26, 2026, at a price of $77.15 per share.
• This acquisition represents a restricted stock award that will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026.
• Carey also disposed of 2,773 shares of common stock on February 28, 2026, at $73.9 per share.
• These disposed shares were withheld for tax purposes, exempt under Rule 16(b)-3, in connection with the vesting of a previously reported grant of 6,079 restricted shares.
• Following these transactions, Carey beneficially owns 189,543 shares of common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive, as the SVP & CFO's acquisition of restricted stock aligns his long-term interests with the company's performance, while the tax-related disposition is a routine event.

Positives

• SVP & CFO Stephen P. Carey acquired 22,233 shares of common stock, aligning his interests with shareholders.
• The acquisition is a restricted stock award, indicating a long-term incentive for management tied to company performance.

Negatives

• 2,773 shares were disposed of for tax withholding purposes, which is a routine event but results in a reduction of direct beneficial ownership.

Future Outlook

The restricted stock award of 22,233 shares will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026.

Industry Context

StockSavvy.ai notes that insider acquisitions, especially restricted stock awards, are common compensation practices designed to align management incentives with long-term shareholder value. These types of transactions are standard for executives and do not typically reflect a change in broader industry trends.

Related Party Transactions

• The restricted stock award is a transaction between the company and its SVP & CFO, Stephen P. Carey, as part of his executive compensation.

Stakeholder Impact

• Shareholders: The acquisition of restricted stock by a key executive can be seen as a positive signal, aligning management's interests with long-term shareholder value.

Next Steps

• The restricted stock award will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (restricted stock award and tax withholding upon vesting). While the acquisition of shares by a key executive is generally a positive signal of alignment, these are not open market purchases indicating a strong belief in immediate upside. The transactions do not provide new fundamental information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

ANIP, ANI Pharmaceuticals, Stephen P. Carey, Form 4, insider transaction, restricted stock award, CFO, beneficial ownership, tax withholding